Dr Reddy’s Laboratories
Dr Reddy’s Laboratories’ Q2 FY07 revenue stood at Rs 20 billion as against Rs 5.8 billion in Q2 FY06, representing an increase of 245 percent. Gross profits increased to Rs 8.3 billion in Q2 FY 07 from Rs 3.0 billion in Q2 FY 06.
Revenues from international markets increased by 391 percent to Rs 17.6 billion, making a contribution of 88 percent to total revenues as compared to 62 percent in Q2 FY06. A noticeable fact was that API revenues in India dropped down to Rs 502 million in Q2 FY 07 as against Rs 578 million in Q2 FY 06, representing decrease of 13 percent, primarily on account of volume decline in key products.
Net R&D investments accounted for two percent of total revenues as against eight percent in Q2 FY 06. Net income was Rs 2,798 million as against Rs 890 million in Q2 FY 06.
Glenmark Pharmaceuticals declared the unaudited financial results for the quarter ending September 2006. According to the results, the net sales for the quarter was recorded as Rs 19,634.98 lakh as compared to Rs 12,559.35 lakh for the same quarter the previous year. Glenmark’s PAT was at Rs 3,205.13 lakh over Rs 1,384.80 for FY05.